Eribulin
Eribulin (pronounced eh-rih-BYOO-lin) is a chemotherapy drug used in the treatment of certain types of cancer, including breast cancer and liposarcoma. It is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai.
Etymology
The name "Eribulin" is derived from the chemical structure of the drug, which is a simplified version of the natural product halichondrin B. The prefix "Eri-" is derived from the genus name of the sponge from which halichondrin B is isolated, Eribulin.
Pharmacology
Eribulin works by inhibiting the growth phase of microtubule dynamics, which prevents cell division and leads to cell death. This is different from other tubulin inhibitors, which also affect the shortening phase of microtubule dynamics.
Usage
Eribulin is used in the treatment of metastatic breast cancer and liposarcoma that has not responded to other treatments. It is usually given by injection into a vein.
Side Effects
Common side effects of eribulin include fatigue, nausea, hair loss, and low blood cell counts. More serious side effects can include nerve damage, heart problems, and severe infections.
Related Terms
External links
- Medical encyclopedia article on Eribulin
- Wikipedia's article - Eribulin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski